Aimmune Therapeutics (AIMT) Price Target Raised to $60.00 at Piper Jaffray Companies

Aimmune Therapeutics (NASDAQ:AIMT) had its price objective boosted by Piper Jaffray Companies from $38.00 to $60.00 in a report published on Tuesday. The firm currently has an overweight rating on the biotechnology company’s stock.

Several other research analysts also recently issued reports on the company. ValuEngine downgraded Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Wedbush reaffirmed an outperform rating and set a $70.00 price objective on shares of Aimmune Therapeutics in a report on Friday, December 1st. Roth Capital assumed coverage on Aimmune Therapeutics in a report on Monday, November 20th. They set a buy rating and a $60.00 price objective on the stock. Zacks Investment Research raised Aimmune Therapeutics from a hold rating to a buy rating and set a $34.00 price objective on the stock in a report on Wednesday, November 8th. Finally, Credit Suisse Group upped their price objective on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an outperform rating in a report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Aimmune Therapeutics has a consensus rating of Hold and an average target price of $53.80.

Aimmune Therapeutics (NASDAQ AIMT) traded up $0.08 during midday trading on Tuesday, reaching $36.28. The company had a trading volume of 300,400 shares, compared to its average volume of 355,100. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. analysts anticipate that Aimmune Therapeutics will post -2.57 earnings per share for the current year.

In related news, insider Douglas T. Sheehy sold 3,750 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $37.00, for a total value of $138,750.00. Following the completion of the sale, the insider now owns 3,750 shares in the company, valued at approximately $138,750. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Stephen George Dilly sold 100,000 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.01, for a total transaction of $2,501,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 303,080 shares of company stock worth $8,134,414. 17.59% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its holdings in Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 499 shares in the last quarter. Legal & General Group Plc increased its holdings in Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 1,634 shares in the last quarter. Voya Investment Management LLC increased its holdings in Aimmune Therapeutics by 31.2% during the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 3,757 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Aimmune Therapeutics during the 2nd quarter worth about $333,000. Finally, Citadel Advisors LLC bought a new position in Aimmune Therapeutics during the 2nd quarter worth about $360,000. Hedge funds and other institutional investors own 73.34% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aimmune Therapeutics (AIMT) Price Target Raised to $60.00 at Piper Jaffray Companies” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://stocknewstimes.com/2017/12/06/aimmune-therapeutics-aimt-price-target-raised-to-60-00-at-piper-jaffray-companies.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply